BusinessNewsTechnology

Cancer Immunotherapy Market Size, Trends,Share and Forecast 2023: Novartis, Amgen Inc., Biovest International Inc, Ablynx NV, Genentech Inc, Bellicum Pharmaceuticals Inc

Cancer Immunotherapy Market

According to Research for Markets, the Global Cancer Immunotherapy market is estimated at $62.57 billion in 2016 and is expected to reach $160.24 billion by 2023 growing at a CAGR of 14.3% from 2016 to 2023. Rapid increase in cases of cancer across the globe, technical advancement in treatment therapies, smoking and excessive consumption of alcohol which causes cancer are some of the factors fueling the market growth. High cost for the treatment and lack of awareness are the restraints hampering the market. On the other hand rise in clinical trials against different cancers in immunotherapy and elevated expansion prediction in developing countries are some opportunities for the market over the forecast period.

Get a  Sample copy of this report: https://www.researchformarkets.com/sample/cancer-immunotherapy-global-market-5208

Cancer Immunotherapy Market Size, Trends,Share and Forecast 2023
Cancer Immunotherapy Market Size, Trends,Share and Forecast 2023

In terms of geography, North America captured largest share owing to high mortality rate among cancer patients and government initiative programs to create awareness among the people. Asia Pacific region is expected to be fastest growing during forecast period.

Some of the key players in the market include Bristol-Myers Squibb, F. Hoffmann-LA Roche Ltd, GlaxoSmithKline, Pfizer, Eli Lilly and Company, Janssen Global Services, LLC (Johnson and Johnson), Novartis, Amgen Inc., Biovest International Inc, Ablynx NV, Genentech Inc, Bellicum Pharmaceuticals Inc, Bayer AG, Oxford BioTherapeutics Ltd., Merck, Sydys Corporation, Dendreon, Xencor, Daiichi Sankyo and TG Therapeutics.

Product Types Covered:
• Immune Checkpoint Inhibitors
o Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)
o Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1)
• Cancer Monoclonal Antibodies
o Conjugated Monoclonal Antibodies
o Bispecific Monoclonal Antibodies
o Naked Monoclonal Antibodies
• Immunomodulators
o Oncolytic Virus
o Interleukins (IL)
o Interferons (IFN)
• Cancer Vaccines
o Prophylactic Vaccines
o Therapeutic Vaccines
• Cell Therapies
o Chimeric Antigen Receptor (CAR) T Cell Therapy
o Dendritic Cells

Cancer Types Covered:
• Breast Cancer
• Colorectal Cancer
• Head & Neck Cancer
• Multiple Myeloma
• Melanoma
• Lung Cancer
• Prostate Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Other Cancer Types

End Users Covered:
• Hospital
• Clinics
• Other End Users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o U.K.
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

Get Discount  on Report: https://www.researchformarkets.com/discount/cancer-immunotherapy-global-market-5208

About us:

Research for Markets indulge in detailed and diligent research on different markets, trends and emerging opportunities in the successive direction to cater to your business needs. We have established the pillars of our flourishing institute on the grounds of Credibility and Reliability. RFM delve into the markets across Asia Pacific, North America, South America, Europe, Middle East and Africa.

 

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

Contact Info:

Name: Research For Markets

Email: alan.naidu@researchformarkets.com

Phone: +44 8000-4182-37

www.researchformarkets.com

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close